NasdaqCM - Nasdaq Real Time Price USD

NRx Pharmaceuticals, Inc. (NRXP)

2.1850 -0.0850 (-3.74%)

As of 2:12:51 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection

MarketBeat 3d ago

NRXP
-3.74%
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

GlobeNewswire 3d ago

NRXP
-3.74%
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine

GlobeNewswire 3d ago

NRXP
-3.74%
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

GlobeNewswire 14d ago

NRXP
-3.74%
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

GlobeNewswire 18d ago

NRXP
-3.74%
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

GlobeNewswire 1mo ago

NRXP
-3.74%
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

GlobeNewswire 1mo ago

NRXP
-3.74%
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire 1mo ago

NRXP
-3.74%
NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...

GuruFocus.com 2mo ago

NRXP
-3.74%
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

GlobeNewswire 2mo ago

NRXP
-3.74%
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

Zacks 2mo ago

NRXP
-3.74%
PHR
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

MarketBeat 2mo ago

NRXP
-3.74%

Performance Overview

Return	NRXP	S&P 500 (^GSPC)
YTD	-18.82%	+10.84%
1-Year	-29.03%	+10.92%
3-Year	-28.57%	+75.72%

U.S. markets close in 1h 47m

NRx Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles